Next Article in Journal
Breakthrough to Non-Vacuum Deposition of Single-Crystal, Ultra-Thin, Homogeneous Nanoparticle Layers: A Better Alternative to Chemical Bath Deposition and Atomic Layer Deposition
Next Article in Special Issue
Recent Advances in Nanomaterials for Gene Delivery—A Review
Previous Article in Journal
Highly Enhanced Photoreductive Degradation of Polybromodiphenyl Ethers with g-C3N4/TiO2 under Visible Light Irradiation
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Nanomaterials 2017, 7(4), 77;

siRNA Delivery Strategies: A Comprehensive Review of Recent Developments

Use-Inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar 470003, India
Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI 48201, USA
Author to whom correspondence should be addressed.
Academic Editor: Thomas Nann
Received: 4 January 2017 / Revised: 7 March 2017 / Accepted: 31 March 2017 / Published: 5 April 2017
(This article belongs to the Special Issue Nanomaterials in Gene Therapy)
PDF [4808 KB, uploaded 5 April 2017]


siRNA is a promising therapeutic solution to address gene overexpression or mutations as a post-transcriptional gene regulation process for several pathological conditions such as viral infections, cancer, genetic disorders, and autoimmune disorders like arthritis. This therapeutic method is currently being actively pursued in cancer therapy because siRNA has been found to suppress the oncogenes and address mutations in tumor suppressor genes and elucidate the key molecules in cellular pathways in cancer. It is also effective in personalized gene therapy for several diseases due to its specificity, adaptability, and broad targeting capability. However, naked siRNA is unstable in the bloodstream and cannot efficiently cross cell membranes besides being immunogenic. Therefore, careful design of the delivery systems is essential to fully utilize the potential of this therapeutic solution. This review presents a comprehensive update on the challenges of siRNA delivery and the current strategies used to develop nanoparticulate delivery systems. View Full-Text
Keywords: siRNA; nanoparticles; delivery systems; cancer therapy; tumor; RNAi; gene delivery; targeted delivery siRNA; nanoparticles; delivery systems; cancer therapy; tumor; RNAi; gene delivery; targeted delivery

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Tatiparti, K.; Sau, S.; Kashaw, S.K.; Iyer, A.K. siRNA Delivery Strategies: A Comprehensive Review of Recent Developments. Nanomaterials 2017, 7, 77.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top